1
|
Zhang Y, Luo Z, Guo L, Zhang H, Su T, Tan Z, Ren Q, Zhang C, Fu Y, Xing R, Guo R, Shi X, Guo H, Liu Y, Wang L. Discovery of novel tumor-targeted near-infrared probes with 6-substituted pyrrolo[2,3-d]pyrimidines as targeting ligands. Eur J Med Chem 2023; 262:115914. [PMID: 37925763 DOI: 10.1016/j.ejmech.2023.115914] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2023] [Revised: 10/19/2023] [Accepted: 10/24/2023] [Indexed: 11/07/2023]
Abstract
Since the overexpression of folate receptors (FRs) in certain types of cancers, a variety of FR-targeted fluorescent probes for tumor detection have been developed. However, the reported probes almost all have the same targeting ligand of folic acid with various fluorophores and/or linkers. In the present study, a series of novel tumor-targeted near-infrared (NIR) molecular fluorescent probes were designed and synthesized based on previously reported 6-substituted pyrrolo[2,3-d]pyrimidine antifolates. All newly synthesized probes showed specific FR binding in vitro, whereas GT-NIR-4 and GT-NIR-5 with a benzene and a thiophene ring, respectively, on the side chain of pyrrolo[2,3-d]pyrimidine exhibited better FR binding affinity than that of GT-NIR-6 with folic acid as targeting ligand. GT-NIR-4 also showed high tumor uptake in KB tumor-bearing mice with good pharmacokinetic properties and biological safety. This work demonstrates the first attempt to replace folic acid with antifolates as targeting ligands for tumor-targeted NIR probes.
Collapse
Affiliation(s)
- Yining Zhang
- Department of Medicinal Chemistry, School of Pharmacy, Hebei Medical University, 361 East Zhongshan Road, Shijiazhuang, 050017, PR China
| | - Zijun Luo
- Department of Medicinal Chemistry, School of Pharmacy, Hebei Medical University, 361 East Zhongshan Road, Shijiazhuang, 050017, PR China
| | - Lixiao Guo
- Department of Medicinal Chemistry, School of Pharmacy, Hebei Medical University, 361 East Zhongshan Road, Shijiazhuang, 050017, PR China
| | - Haofeng Zhang
- Department of Medicinal Chemistry, School of Pharmacy, Hebei Medical University, 361 East Zhongshan Road, Shijiazhuang, 050017, PR China
| | - Tongdan Su
- Department of Medicinal Chemistry, School of Pharmacy, Hebei Medical University, 361 East Zhongshan Road, Shijiazhuang, 050017, PR China
| | - Zhenzhen Tan
- Department of Toxicology, School of Public Health, Hebei Medical University, 361 East Zhongshan Road, Shijiazhuang, 050017, PR China
| | - Qian Ren
- Department of Toxicology, School of Public Health, Hebei Medical University, 361 East Zhongshan Road, Shijiazhuang, 050017, PR China
| | - Can Zhang
- Department of Toxicology, School of Public Health, Hebei Medical University, 361 East Zhongshan Road, Shijiazhuang, 050017, PR China
| | - Yan Fu
- Core Facilities and Centers, Hebei Medical University, 361 East Zhongshan Road, Shijiazhuang, 050017, PR China
| | - Ruijuan Xing
- Department of Medicinal Chemistry, School of Pharmacy, Hebei Medical University, 361 East Zhongshan Road, Shijiazhuang, 050017, PR China
| | - Ran Guo
- Department of Medicinal Chemistry, School of Pharmacy, Hebei Medical University, 361 East Zhongshan Road, Shijiazhuang, 050017, PR China
| | - Xiaowei Shi
- Department of Medicinal Chemistry, School of Pharmacy, Hebei Medical University, 361 East Zhongshan Road, Shijiazhuang, 050017, PR China
| | - Huicai Guo
- Department of Toxicology, School of Public Health, Hebei Medical University, 361 East Zhongshan Road, Shijiazhuang, 050017, PR China
| | - Yi Liu
- Department of Toxicology, School of Public Health, Hebei Medical University, 361 East Zhongshan Road, Shijiazhuang, 050017, PR China; Hebei Key Laboratory of Environment and Human Health, Shijiazhuang, 050017, PR China.
| | - Lei Wang
- Department of Medicinal Chemistry, School of Pharmacy, Hebei Medical University, 361 East Zhongshan Road, Shijiazhuang, 050017, PR China; Hebei Key Laboratory of Innovative Drug Research and Evaluation, Shijiazhuang, 050017, PR China.
| |
Collapse
|
2
|
Alam MM, Elbehairi SEI, Shati AA, Hussien RA, Alfaifi MY, Malebari AM, Asad M, Elhenawy AA, Asiri AM, Mahzari AM, Alshehri RF, Nazreen S. Design, synthesis and biological evaluation of new eugenol derivatives containing 1,3,4-oxadiazole as novel inhibitors of thymidylate synthase. NEW J CHEM 2023. [DOI: 10.1039/d2nj05711e] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
Abstract
We report the preparation and cytotoxicity of two new eugenol derivatives that contain 1,3,4-oxadiazole, as novel inhibitors of thymidylate synthase; these derivatives are shown to be promising chemotherapeutic agents.
Collapse
Affiliation(s)
- Mohammad Mahboob Alam
- Department of Chemistry, Faculty of Science, Al-Baha University, Al-Baha, Kingdom of Saudi Arabia
| | - Serag Eldin I. Elbehairi
- Department of Biology, Faculty of Science, King Khalid University, Abha 9004, Saudi Arabia
- Cell Culture Laboratory, Egyptian Organization for Biological Products and Vaccines, VACSERA Holding Company, Giza 2311, Egypt
| | - Ali A. Shati
- Department of Biology, Faculty of Science, King Khalid University, Abha 9004, Saudi Arabia
| | - Rania A. Hussien
- Department of Chemistry, Faculty of Science, Al-Baha University, Al-Baha, Kingdom of Saudi Arabia
| | - Mohammad Y. Alfaifi
- Department of Biology, Faculty of Science, King Khalid University, Abha 9004, Saudi Arabia
| | - Azizah M. Malebari
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia
| | - Mohammad Asad
- Center of Excellence for Advanced Materials Research (CEAMR), King Abdulaziz University, P.O. Box 80203, Jeddah 21589, Saudi Arabia
- Chemistry Department, Faculty of Science, King Abdulaziz University, P.O. Box 80203, Jeddah 21589, Saudi Arabia
| | - Ahmed A. Elhenawy
- Department of Chemistry, Faculty of Science, Al-Baha University, Al-Baha, Kingdom of Saudi Arabia
- Chemistry Department, Faculty of Science, Al-Azhar University, 11884 Nasr City, Cairo, Egypt
| | - Abdullah M. Asiri
- Center of Excellence for Advanced Materials Research (CEAMR), King Abdulaziz University, P.O. Box 80203, Jeddah 21589, Saudi Arabia
- Chemistry Department, Faculty of Science, King Abdulaziz University, P.O. Box 80203, Jeddah 21589, Saudi Arabia
| | - Ali M. Mahzari
- Department of Laboratory Medicine, Faculty of Applied Medical Sciences, Al Baha University, Al Baha, Saudi Arabia
| | - Reem F. Alshehri
- Chemistry Department, Faculty of Science and Art, Al Ula, Taibah University, Al Madinah, Kingdom of Saudi Arabia
| | - Syed Nazreen
- Department of Chemistry, Faculty of Science, Al-Baha University, Al-Baha, Kingdom of Saudi Arabia
| |
Collapse
|
3
|
Xiang J, Wu M, Wang J, Lin M, Sun M, Li X, Xing R, Guo R, Gu J, Lyu T, Wang L, Shi X. Pharmacokinetics, bioavailability, and plasma protein binding study of glytrexate, a novel multitarget antifolate. Front Pharmacol 2022; 13:1001308. [PMID: 36267288 PMCID: PMC9577195 DOI: 10.3389/fphar.2022.1001308] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2022] [Accepted: 09/15/2022] [Indexed: 11/13/2022] Open
Abstract
Glytrexate, developed by our team, as a novel multitarget folate antagonist, has inhibitory effects on a variety of cancer cell types, especially KB tumor cells (IC50 0.078 nM), and thus has antitumor drug development prospects. However, its pharmacokinetics and plasma protein binding properties remain unknown. In this study a selective and sensitive liquid chromatography-tandem mass spectrometry (LC‒MS/MS) method was developed and verified to facilitate biological analysis. The bioanalysis method was applied to evaluate the stability, plasma protein binding, and pharmacokinetics of glytrexate. Glytrexate is more stable in human plasma than in rat plasma and in human liver microsomes. The binding of glytrexate to human plasma proteins was higher than that to rat plasma proteins, both of which were less than 30%, suggesting that glytrexate may be at a higher concentration at the pharmacologic target receptor(s) in tissues. Pharmacokinetic characteristics were determined by noncompartmental analysis after administration of single oral (12.5, 25 and 50 mg/kg) and intravenous (2 mg/kg) doses in rats. According to the rat oral pharmacokinetic characteristics, glytrexate had linear dynamics in a dose range of 12.5–50 mg/kg and a poor oral bioavailability of 0.57–1.15%. The investigation revealed that the intravenous half-life, AUC, and Cmax of glytrexate were higher than those of pemetrexed. Pemetrexed is generally produced as an injection preparation. This provides ideas for the development of glytrexate formulations. Therefore, glytrexate injection has clinical application prospects compared to oral administration. This study provides a basis for further investigations into the pharmacological effects and clinical uses of glytrexate.
Collapse
Affiliation(s)
- Jiahong Xiang
- Key Laboratory of Innovative Drug Research and Evaluation in Hebei Province, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang, China
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang, China
| | - Mengqi Wu
- Key Laboratory of Innovative Drug Research and Evaluation in Hebei Province, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang, China
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang, China
| | - Jianchao Wang
- Key Laboratory of Innovative Drug Research and Evaluation in Hebei Province, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang, China
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang, China
| | - Mengmeng Lin
- Key Laboratory of Innovative Drug Research and Evaluation in Hebei Province, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang, China
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang, China
| | - Mengmeng Sun
- Department of General Practice, The Second Hospital, Hebei Medical University, Shijiazhuang, China
| | - Xin Li
- Key Laboratory of Innovative Drug Research and Evaluation in Hebei Province, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang, China
| | - Ruijuan Xing
- Key Laboratory of Innovative Drug Research and Evaluation in Hebei Province, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang, China
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang, China
| | - Ran Guo
- Key Laboratory of Innovative Drug Research and Evaluation in Hebei Province, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang, China
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang, China
| | - Jianmin Gu
- Key Laboratory of Innovative Drug Research and Evaluation in Hebei Province, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang, China
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang, China
| | - Tao Lyu
- Key Laboratory of Innovative Drug Research and Evaluation in Hebei Province, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang, China
| | - Lei Wang
- Key Laboratory of Innovative Drug Research and Evaluation in Hebei Province, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang, China
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang, China
- *Correspondence: Xiaowei Shi, ; Lei Wang,
| | - Xiaowei Shi
- Key Laboratory of Innovative Drug Research and Evaluation in Hebei Province, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang, China
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang, China
- *Correspondence: Xiaowei Shi, ; Lei Wang,
| |
Collapse
|
4
|
Almalki ASA, Nazreen S, Elbehairi SEI, Asad M, Shati AA, Alfaifi MY, Alhadhrami A, Elhenawy AA, Alorabi AQ, Asiri AM, Alam MM. Design, synthesis, anticancer activity and molecular docking studies of new benzimidazole derivatives bearing 1,3,4-oxadiazole moieties as potential thymidylate synthase inhibitors. NEW J CHEM 2022. [DOI: 10.1039/d2nj01980a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Compounds 10 and 14 arrest the cell cycle at the G1 phase and induce apoptosis without any necrosis in MDA-MB-231 cells.
Collapse
Affiliation(s)
- Abdulraheem SA Almalki
- Department of Chemistry, Faculty of Science, Taif University, Taif, Kingdom of Saudi Arabia
| | - Syed Nazreen
- Department of Chemistry, Faculty of Science, Al-Baha University, Al-Baha, Kingdom of Saudi Arabia
| | - Serag Eldin I. Elbehairi
- Department of Biology, Faculty of Science, King Khalid University, Abha 9004, Saudi Arabia
- Cell Culture Laboratory, Egyptian Organization for Biological Products and Vaccines, VACSERA Holding Company, Giza 2311, Egypt
| | - Mohammad Asad
- Center of Excellence for Advanced Materials Research (CEAMR), King Abdulaziz University, P.O. Box 80203, Jeddah 21589, Saudi Arabia
- Chemistry Department, Faculty of Science, King Abdulaziz University, P.O. Box 80203, Jeddah 21589, Saudi Arabia
| | - Ali A. Shati
- Department of Biology, Faculty of Science, King Khalid University, Abha 9004, Saudi Arabia
| | - Mohammad Y. Alfaifi
- Department of Biology, Faculty of Science, King Khalid University, Abha 9004, Saudi Arabia
| | - Abdulrahman Alhadhrami
- Department of Chemistry, Faculty of Science, Taif University, Taif, Kingdom of Saudi Arabia
| | - Ahmed A. Elhenawy
- Department of Chemistry, Faculty of Science, Al-Baha University, Al-Baha, Kingdom of Saudi Arabia
- Chemistry Department, Faculty of Science, Al-Azhar University, 11884 Nasr City, Cairo, Egypt
| | - Ali Q. Alorabi
- Department of Chemistry, Faculty of Science, Al-Baha University, Al-Baha, Kingdom of Saudi Arabia
| | - Abdullah M. Asiri
- Center of Excellence for Advanced Materials Research (CEAMR), King Abdulaziz University, P.O. Box 80203, Jeddah 21589, Saudi Arabia
- Chemistry Department, Faculty of Science, King Abdulaziz University, P.O. Box 80203, Jeddah 21589, Saudi Arabia
| | - Mohammad Mahboob Alam
- Department of Chemistry, Faculty of Science, Al-Baha University, Al-Baha, Kingdom of Saudi Arabia
| |
Collapse
|
5
|
Moreno LM, Quiroga J, Abonia R, Lauria A, Martorana A, Insuasty H, Insuasty B. Synthesis, biological evaluation, and in silico studies of novel chalcone- and pyrazoline-based 1,3,5-triazines as potential anticancer agents. RSC Adv 2020; 10:34114-34129. [PMID: 35519030 PMCID: PMC9056798 DOI: 10.1039/d0ra06799g] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2020] [Accepted: 09/09/2020] [Indexed: 12/17/2022] Open
Abstract
A novel series of triazin-chalcones (7,8)a-g and triazin-N-(3,5-dichlorophenyl)pyrazolines (9,10)a-g were synthesized and evaluated for their anticancer activity against nine different cancer strains. Triazine ketones 5 and 6 were synthesized from the cyanuric chloride 1 by using stepwise nucleophilic substitution of the chlorine atom. These ketones were subsequently subjected to a Claisen-Schmidt condensation reaction with aromatic aldehydes affording chalcones (7,8)a-g. Then, N-(3,5-dichlorophenyl)pyrazolines (9,10)a-g were obtained by cyclocondensation reactions of the respective chalcones (7,8)a-g with 3,5-dichlorophenylhydrazine. Among all the evaluated compounds, chalcones 7d,g and 8g exhibited more potent in vitro anticancer activity, with outstanding GI50 values ranging from 0.422 to 14.9 μM and LC50 values ranging from 5.08 μM to >100 μM. In silico studies, for both ligand- and structure-based, were executed to explore the inhibitory nature of chalcones and triazine derivatives. The results suggested that the evaluated compounds could act as modulators of the human thymidylate synthase enzyme.
Collapse
Affiliation(s)
- Leydi M Moreno
- Heterocyclic Compounds Research Group, Department of Chemistry, Universidad del Valle A.A. 25360 Cali Colombia
| | - Jairo Quiroga
- Heterocyclic Compounds Research Group, Department of Chemistry, Universidad del Valle A.A. 25360 Cali Colombia
- Center for Bioinformatics and Photonics-CIBioFI A.A. 25360 Cali Colombia
| | - Rodrigo Abonia
- Heterocyclic Compounds Research Group, Department of Chemistry, Universidad del Valle A.A. 25360 Cali Colombia
- Center for Bioinformatics and Photonics-CIBioFI A.A. 25360 Cali Colombia
| | - Antonino Lauria
- Dipartimento di Scienze e Tecnologie Biologiche Chimiche e Farmaceutiche "STEBICEF", Università di Palermo Viale delle Scienze Ed. 17 I-90128 Palermo Italy
| | - Annamaria Martorana
- Dipartimento di Scienze e Tecnologie Biologiche Chimiche e Farmaceutiche "STEBICEF", Università di Palermo Viale delle Scienze Ed. 17 I-90128 Palermo Italy
| | - Henry Insuasty
- Heterocyclic Compounds Research Group, Department of Chemistry, Universidad de Nariño A.A. 1175 Pasto Colombia
| | - Braulio Insuasty
- Heterocyclic Compounds Research Group, Department of Chemistry, Universidad del Valle A.A. 25360 Cali Colombia
- Center for Bioinformatics and Photonics-CIBioFI A.A. 25360 Cali Colombia
| |
Collapse
|
6
|
Gao T, Zhang C, Shi X, Guo R, Zhang K, Gu J, Li L, Li S, Zheng Q, Cui M, Cui M, Gao X, Liu Y, Wang L. Targeting dihydrofolate reductase: Design, synthesis and biological evaluation of novel 6-substituted pyrrolo[2,3-d]pyrimidines as nonclassical antifolates and as potential antitumor agents. Eur J Med Chem 2019; 178:329-340. [PMID: 31200235 DOI: 10.1016/j.ejmech.2019.06.013] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2019] [Revised: 06/04/2019] [Accepted: 06/04/2019] [Indexed: 10/26/2022]
Abstract
A novel series of 6-substituted pyrrolo[2,3-d]pyrimidines with reversed amide moieties from the lead compound 1a were designed and synthesized as nonclassical antifolates and as potential antitumor agents. Target compounds 1-9 were successfully obtained through two sequential condensation reactions from the key intermediate 2-amino-6-(2-aminoethyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one. In preliminary antiproliferation assay, all compounds demonstrated submicromolar to nanomolar inhibitory effects against KB tumor cells, whereas compounds 1-3 also exhibited nanomolar antiproliferative activities toward SW620 and A549 cells. In particular, compounds 1-3 were significantly more potent than the positive control methotrexate (MTX) and pemetrexed (PMX) to A549 cells. The growth inhibition induced cell cycle arrest at G1-phase with S-phase suppression. Along with the results of nucleoside protection assays, inhibition assays of dihydrofolate reductase (DHFR) clearly elucidated that the intracellular target of the designed compounds was DHFR. Molecular modeling studies suggested two binding modes of the target compounds with DHFR.
Collapse
Affiliation(s)
- Tianfeng Gao
- Department of Medicinal Chemistry, School of Pharmacy, Hebei Medical University, Shijiazhuang, 050017, PR China
| | - Congying Zhang
- Department of Medicinal Chemistry, School of Pharmacy, Hebei Medical University, Shijiazhuang, 050017, PR China
| | - Xiaowei Shi
- Department of Medicinal Chemistry, School of Pharmacy, Hebei Medical University, Shijiazhuang, 050017, PR China
| | - Ran Guo
- Department of Medicinal Chemistry, School of Pharmacy, Hebei Medical University, Shijiazhuang, 050017, PR China
| | - Kai Zhang
- Department of Medicinal Chemistry, School of Pharmacy, Hebei Medical University, Shijiazhuang, 050017, PR China
| | - Jianmin Gu
- Department of Medicinal Chemistry, School of Pharmacy, Hebei Medical University, Shijiazhuang, 050017, PR China
| | - Lin Li
- Department of Medicinal Chemistry, School of Pharmacy, Hebei Medical University, Shijiazhuang, 050017, PR China
| | - Shuolei Li
- Department of Medicinal Chemistry, School of Pharmacy, Hebei Medical University, Shijiazhuang, 050017, PR China
| | - Qianqian Zheng
- Department of Medicinal Chemistry, School of Pharmacy, Hebei Medical University, Shijiazhuang, 050017, PR China
| | - Mengyu Cui
- Department of Medicinal Chemistry, School of Pharmacy, Hebei Medical University, Shijiazhuang, 050017, PR China
| | - Miao Cui
- Department of Medicinal Chemistry, School of Pharmacy, Hebei Medical University, Shijiazhuang, 050017, PR China
| | - Xingmei Gao
- Department of Toxicology, School of Public Health, Hebei Medical University, Shijiazhuang, 050017, PR China
| | - Yi Liu
- Department of Toxicology, School of Public Health, Hebei Medical University, Shijiazhuang, 050017, PR China; Hebei Province Key Laboratory of Environment and Human Health, Shijiazhuang, 050017, PR China.
| | - Lei Wang
- Department of Medicinal Chemistry, School of Pharmacy, Hebei Medical University, Shijiazhuang, 050017, PR China; Hebei Province Key Laboratory of Innovative Drug Research and Evaluation, Shijiazhuang, 050017, PR China.
| |
Collapse
|
7
|
Lu GQ, Li XY, Mohamed O K, Wang D, Meng FH. Design, synthesis and biological evaluation of novel uracil derivatives bearing 1, 2, 3-triazole moiety as thymidylate synthase (TS) inhibitors and as potential antitumor drugs. Eur J Med Chem 2019; 171:282-296. [DOI: 10.1016/j.ejmech.2019.03.047] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2019] [Revised: 03/18/2019] [Accepted: 03/19/2019] [Indexed: 12/28/2022]
|
8
|
Kysil A, Biitseva A, Yegorova T, Levkov I, Voitenko Z. Reaction of 1-aminoisoindole with methyl 4-chloro-3-oxobutanoate. FRENCH-UKRAINIAN JOURNAL OF CHEMISTRY 2018. [DOI: 10.17721/fujcv6i2p32-37] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
Condensation of bifunctional 1-aminoisoindole with bis-electrophilic methyl 4-chloro-3-oxobutanoate undergoes regioselectively to afford 2-(chloromethyl)-2-hydroxy-2,6-dihydropyrimido[2,1-a]isoindol-4(3H)-one. The structure of the reaction product was unambiguously established by HMQC and HMBC heteronuclear correlations. The functionalization of the synthesized compound by reactions with a series of aliphatic amines was carried out.
Collapse
Affiliation(s)
| | | | | | - Igor Levkov
- Taras Shevchenko National University of Kyiv
| | | |
Collapse
|